Underutilization of radiotherapy for lung cancer in New South Wales, Australia.
BACKGROUND
Lung cancer is the leading cause of cancer death in most developed countries. Radiotherapy is important in its treatment, with an estimated optimal utilization rate between 45% and 68% at initial diagnosis. The objective of this study was to describe radiotherapy practice for lung cancer in New South Wales (NSW), Australia.


METHODS
Patients with lung cancer were identified prospectively from the NSW Central Cancer Registry (CCR) from November 1, 2001 to December 31, 2002. Questionnaires were mailed to diagnosing and treating clinicians to obtain detailed information on diagnosis, staging, referrals, and treatment. The authors describe referral for and receipt of radiotherapy treatment.


RESULTS
Of 1812 patients with lung cancer patients who were identified, 943 patients (52%) were referred for radiotherapy, 846 patients (47%) received a radiotherapy questionnaire, and 727 patients (40%) received radiotherapy. Compared with optimal radiotherapy, there was less curative radiotherapy to the primary site (20% actual vs 50% optimal), and there was more palliative radiotherapy to metastatic sites (36% actual vs 11% optimal). The greatest shortfall in radiotherapy use was observed in patients who had limited stage small cell lung cancer (46% actual vs 94% optimal). The use of combined-modality treatment for stage III nonsmall cell lung cancer and for limited stage small cell lung cancer was uncommon.


CONCLUSIONS
There is underutilization of radiotherapy for lung cancer in NSW, especially in small cell lung cancer. The use of combined-modality treatment for potentially curable lung cancers is suboptimal. These issues have to be addressed to improve survival and quality of life for patients with lung cancer.
Vinod
Shalini K
SK
Collaboration for Cancer Outcomes, Research, and Evaluation, Liverpool Hospital, University of New South Wales, Liverpool, New South Wales, Australia.
Simonella
Leonardo
L
Goldsbury
David
D
Delaney
Geoff P
GP
Armstrong
Bruce
B
O'Connell
Dianne L
DL
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001315:Australia; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000532:radiotherapy*; D003131:Combined Modality Therapy; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*; D008875:Middle Aged; D009517:New South Wales; D010818:Practice Patterns, Physicians'; D011878:Radiotherapy / Q000706:statistics & numerical data*; D018714:Radiotherapy, Adjuvant; D055752:Small Cell Lung Carcinoma / Q000188:drug therapy / Q000532:radiotherapy*
D000970:Antineoplastic Agents